Associated tags: Fermentation, CDMO, Research, GMP, Employment, Patient, Fine chemical, DSM-IV codes, Mustang, Cancer, Pharmaceutical industry, CGMP, CAR, Translation, Waldenström, WM, Security, PSCA, Hematological Cancer Research Investment and Education Act, City, Birmingham, XSCID, Vaccine
Locations: BOSTON
Employment,
Chronic lymphocytic leukemia,
Non-Hodgkin lymphoma,
Translation,
CAR,
CFIUS,
CGMP,
Patient,
Cancer,
Form,
Foreign investment,
Mustang,
DSM-IV codes,
Pharmaceutical industry,
Lease,
Fine chemical Unless and until the lease is transferred to uBriGene, Mustang will retain its facility lease and facility personnel, and will continue to occupy the leasehold premises and manufacture there its lead product candidate, MB-106.
Key Points:
- Unless and until the lease is transferred to uBriGene, Mustang will retain its facility lease and facility personnel, and will continue to occupy the leasehold premises and manufacture there its lead product candidate, MB-106.
- The amended asset purchase agreement provides that Mustang will continue to work with uBriGene to secure the assignment of its manufacturing facility lease, which would complete the transfer of its facility to uBriGene as originally planned.
- At closing, Mustang and uBriGene also entered into a manufacturing services agreement, under which Mustang contracted uBriGene to manufacture Mustang’s lead product candidates.
- Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, commented, “We are very pleased to have closed this strategic transaction with uBriGene.
Waldenström macroglobulinemia,
Partnership,
City of Hope,
Mayo Clinic,
Employment,
Birmingham School of Law,
Malignancy,
University,
GBM,
CD20,
Fred Hutchinson Cancer Research Center,
Neoplasm,
Biotechnology,
Lead,
University of Massachusetts Chan Medical School,
Translation,
Sale,
WM,
Security,
CAR,
PSCA,
CDMO,
Hematological Cancer Research Investment and Education Act,
City,
Waldenström,
Acquisition,
CGMP,
Patient,
Cancer,
XSCID,
Birmingham,
Ecosystem,
Nationwide,
Mustang,
IND,
DSM-IV codes,
Leiden University,
Vaccine,
Bank,
Pharmaceutical industry,
Fine chemical,
Greater Boston WORCESTER, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
Key Points:
- Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology.
- Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
- Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang’s lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.
- I want to thank our manufacturing team for their dedication in building and growing our Worcester facility since it opened in 2018.
